Volume 55, Issue 6pt2 pp. 1411-1417
RH SYSTEM

RHD variants in Flanders, Belgium

Vicky S.T. Van Sandt

Vicky S.T. Van Sandt

Histocompatibility and Immunogenetic Laboratory, Red Cross Flanders, Mechelen, Belgium

VSTVS and CG contributed equally to this study.Search for more papers by this author
Christoph Gassner

Christoph Gassner

Blood Transfusion Service Zürich, Swiss Red Cross, Schlieren, Switzerland

VSTVS and CG contributed equally to this study.Search for more papers by this author
Marie-Paule Emonds

Marie-Paule Emonds

Histocompatibility and Immunogenetic Laboratory, Red Cross Flanders, Mechelen, Belgium

Search for more papers by this author
Tobias J. Legler

Tobias J. Legler

Department of Transfusion Medicine, University of Göttingen, Göttingen, Germany

Search for more papers by this author
Sarah Mahieu

Sarah Mahieu

Histocompatibility and Immunogenetic Laboratory, Red Cross Flanders, Mechelen, Belgium

ZNA Stuivenberg, Antwerp, Belgium

Search for more papers by this author
Günther F. Körmöczi

Corresponding Author

Günther F. Körmöczi

Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria

Address reprint requests to: Günther Körmöczi, Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria; e-mail: [email protected].Search for more papers by this author
First published: 21 November 2014
Citations: 22

Abstract

Background

D antigen variants may be grouped into partial D, weak D, and DEL types. Cumulative phenotype frequencies of these D variants may approach 1% in certain European regions. Unambiguous and quick identification of D variants is of immediate clinical relevance, with implications for transfusion strategy.

Study Design and Methods

A total of 628 samples with ambiguous serologic results from different immunohematology laboratories throughout the Flanders region, Belgium, were genotyped using a commercially available weak D typing approach. After exclusion of detectable weak D types, molecular RHD exon scanning was performed for the remaining samples, and RHD sequencing was performed in two particular cases.

Results

Of all samples investigated, 424 (67.5%) were positive for weak D Type 1, 2, or 3, and 22 cases (3.5%) typed weak D Type 4.0/4.1/4.3, 4.2, 5, 11, 15, or 17. Another 49 (7.8%) samples were partial D variants, with a major proportion being category DVI types (n = 27). One RHD(S103P) sample was identified as high-grade partial D, with DIII-like phenotype and anti-D and anti-C immunization. Additionally, a novel DVI Type 3 (A399T) variant was found. Of the remaining 133 samples mainly tested because of ambiguous serologic D typing results due to recent transfusion, 32 (5.1%) were negative for RHD, and 101 (16.1%) were indistinguishable from wild-type RHD and not investigated further.

Conclusion

Despite the enormous diversity of RHD alleles, first-line weak D genotyping was remarkably informative, allowing for rapid classification of most samples with conspicuous RhD phenotype in Flanders. The clinical implications are discussed.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.